The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.leukres.2018.02.011PMID 29477024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.

  2017cited by this paper
• Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis

  2017cited by this paper
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

  2016cited by this paper
• The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified

  2016cited by this paper
• Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer

  2015cited by this paper
• Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia

  2014cited by this paper
• Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis

  2014cited by this paper
• Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio

  2014cited by this paper
• The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer

  2014cited by this paper
• The role of inflammation in lymphoma.

  2014cited by this paper
• An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

  2014cited by this paper
• A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.

  2013cited by this paper
• External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients

  2013cited by this paper
• The World Health Organization Classification of Lymphoid Neoplasms

  2013cited by this paper
• Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.

  2012cited by this paper
• The prognostic significance of lymphopenia in peripheral T‐cell and natural killer/T‐cell lymphomas: A study of 826 cases from the International Peripheral T‐cell Lymphoma Project

  2012cited by this paper
• Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratio

  2010cited by this paper
• Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified

  2010cited by this paper
• Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios

  2010cited by this paper
• Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

  2010cited by this paper
• Cancer-related inflammation

  2008cited by this paper
• Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study

  2008cited by this paper
• Distribution and Pathology Characteristics of Non Hodgkin Lymphoma in Peru: A Study of 1014 Cases Using WHO Classification of Lymphoid Neoplasm.

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

  2006cited by this paper
• Pyothorax-Associated Lymphoma: A Lymphoma Developing in Chronic Inflammation

  2005cited by this paper
• Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

  2001cited by this paper
• Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.

  1995cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome.

  1984cited by this paper

• Assessment of the neutrophil-to-lymphocyte ratio as a prognostic marker in patients with newly diagnosed diffuse large B-cell lymphoma: A Colombian Cohort Study

  2025cites this paper
• Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence

  2025influential citation
• Impact of Neutrophil-Lymphocyte Ratio in Acral Lentiginous melanoma

  2024cites this paper
• An explanatory model of depressive symptoms from anxiety, post-traumatic stress, somatic symptoms, and symptom perception: the potential role of inflammatory markers in hospitalized COVID-19 patients

  2022cites this paper
• Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System

  2022cites this paper
• Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma

  2021cites this paper
• Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma.

  2021cites this paper
• Low Prognostic Nutritional Index Indicates Dismal Prognosis in Patients with Diffuse Large B Cell Lymphoma

  2020cites this paper
• A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL).

  2020cites this paper
• Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy

  2019cites this paper
• High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.

  2019cites this paper
• Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma

  2019cites this paper